Merck MRK and its Japanese partner Eisai said Friday they are discontinuing the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma after data showed the combination did not produce an improvement in overall survival, or OS, compared wi
Full Story >>
Vote
+83